tiprankstipranks
Tarsus Pharmaceuticals (TARS)
NASDAQ:TARS
US Market

Tarsus Pharmaceuticals (TARS) Earnings Dates, Call Summary & Reports

Compare
216 Followers

Earnings Data

Report Date
Feb 25, 2025
TBA Not Confirmed
Period Ending
2024 (Q4)
Consensus EPS Forecast
-0.74
Last Year’s EPS
-1.31
Same Quarter Last Year
Based on 8 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Feb 25, 2025
|
% Change Since: -6.54%
|
Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted a year of strong financial performance and strategic advancements in Tarsus' pipeline, particularly with the success of XDEMVY and preparations for future product launches. However, challenges such as increased operational costs and anticipated headwinds in early 2025 were noted.
Company Guidance
In the 2024 financial results call, Tarsus reported $180.1 million in net product sales for XDEMVY, with more than 163,000 bottles delivered. The sales force was expanded from 100 to 150 representatives, leading to over 15,000 eye care physicians prescribing the product. XDEMVY achieved over 90% commercial and Medicare coverage, with a gross-to-net discount of approximately 45%. The company plans continued investment in a direct-to-consumer advertising campaign, which is expected to cost $60 to $70 million annually. Tarsus also announced plans to advance their pipeline with a Phase 2 trial for TP-04 in Ocular Rosacea and the potential for a Phase 2 study of TP-05 for Lyme disease prevention in 2026, aiming for a steady-state gross-to-net discount in the low 40s by the end of 2025.
Record-Breaking Financial Performance
In 2024, Tarsus reported more than $180 million in net product sales for XDEMVY, with over 163,000 bottles delivered to patients.
Expanded Sales Force and Coverage
The sales force was expanded from 100 to 150 representatives, leading to more than 15,000 eye care physicians prescribing XDEMVY. Coverage now extends to over 90% of potential patient lives.
Positive Pipeline Developments
Significant progress in advancing the pipeline, including plans for a Phase 2 trial of TP-04 for Ocular Rosacea and a clear regulatory path for TP-05 in Lyme disease prevention.
Successful Direct-to-Consumer Campaign
The launch of a direct-to-consumer advertising campaign, including network TV placements, has generated increased patient engagement and visits to eye care professionals.
High Gross Margins
Tarsus reported gross margins of approximately 93%, showcasing effective cost management alongside strong sales performance.
---

Tarsus Pharmaceuticals (TARS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

TARS Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
May 13, 20252025 (Q1)
-0.79 / -
-1.01
Feb 25, 20252024 (Q4)
-0.74 / -0.60
-1.3154.20% (+0.71)
Nov 13, 20242024 (Q3)
-0.94 / -0.61
-1.2852.34% (+0.67)
Aug 08, 20242024 (Q2)
-0.92 / -0.88
-1.1724.79% (+0.29)
May 08, 20242024 (Q1)
-1.18 / -1.01
-0.88-14.77% (-0.13)
Feb 27, 20242023 (Q4)
-1.37 / -1.31
-0.46-184.78% (-0.85)
Nov 09, 20232023 (Q3)
-1.35 / -1.28
-0.84-52.38% (-0.44)
Aug 10, 20232023 (Q2)
-1.08 / -1.17
-0.24-387.50% (-0.93)
May 09, 20232023 (Q1)
-0.96 / -0.88
-0.9810.20% (+0.10)
Mar 13, 20232022 (Q4)
-0.67 / -0.46
-0.7236.11% (+0.26)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

TARS Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 25, 2025$45.54$41.29-9.33%
Nov 13, 2024$46.50$46.65+0.32%
Aug 08, 2024$23.61$26.85+13.72%
May 08, 2024$37.35$34.04-8.86%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Tarsus Pharmaceuticals (TARS) report earnings?
Tarsus Pharmaceuticals (TARS) is schdueled to report earning on Feb 25, 2025, TBA Not Confirmed.
    What is Tarsus Pharmaceuticals (TARS) earnings time?
    Tarsus Pharmaceuticals (TARS) earnings time is at Feb 25, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is TARS EPS forecast?
          TARS EPS forecast for the fiscal quarter 2024 (Q4) is -0.74.
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis